GVR Report cover Clinical Trials Matching Software Market Size, Share & Trends Report

Clinical Trials Matching Software Market Size, Share & Trends Analysis Report By Deployment Mode (Web & Cloud Based, On-premise), By End Use, By Region, And Segment Forecasts, 2022 - 2030

  • Published Date: Apr 2022
  • Report ID: GVR-4-68039-921-8
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2020

Report Overview                                                      

The global clinical trials matching software market size was valued at USD 132.8 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 13.8% from 2022 to 2030. Pharmaceutical manufacturers, biotechnology companies, clinical research organizations (CROs), and medical device manufacturers frequently conduct clinical trials to test the safety and efficacy of novel medications, diagnostics, and therapies. The rising prevalence of chronic diseases and the growing need for clinical trials are expected to contribute to the market growth. Clinical trials are increasingly conducted in developing regions as the availability for patient recruitment and matching is a crucial part of clinical trials.

U.S. clinical trials matching software market size, by deployment mode, 2020 - 2030 (USD Million)

The COVID-19 pandemic had a significant impact, particularly on the hospitals, due to the patient load and the danger of viral propagation. To counteract the virus's transmission among doctors, hospital workers, and patients, healthcare facilities have altered the execution of clinical trials. The restrictions and limitations impacted a number of ongoing clinical studies in various therapeutic areas. In order to overcome the adverse situation, researchers created novel COVID-19 vaccines. The growing demand for services from the CROs to perform clinical trials in the pharmaceutical industry is driving the market.

The digitization of research is also opening the door for market expansion. Incorporating sophisticated technology such as Electronic Data Capture (EDC), and clinical trials management systems assist market players in maintaining patient data and lowering monitoring expenses. Hence, clinical trial matching software can be crucial in conducting trials and improving the efficiency of the process. Regulatory authorities such as the European Medicines Agency (EMA), U.S. FDA, China’s National Medical Products Administration, and the National Institutes of Health (NIH) have released a framework for the conduct of clinical studies during the pandemic, which fully supports the virtual trials. This acceptance by regulatory authorities and pharmaceutical companies is anticipated to fuel the growth of the patient matching software market.

In clinical trials, patient matching is an essential factor as trials are performed on humans and the right candidate match can save the time of the sponsors, thereby leading to optimal results. A lot of pharmaceutical companies, research organizations, and hospitals are shifting towards virtual or remote trials. These trials do not require traveling to sites and the process is conducted online. Hence, the future of clinical trials lies in clinical trial management systems and patient matching software. These automated systems eliminate the need for human intervention, hence contributing to the growing demand for patient matching software.

This patient matching software provides patient centricity, which is a significant aspect in comparison with the traditional method. In addition, it provides data transparency and faster recruitment, which saves time. To make the process effective, patients answer a couple of questions, which helps them find the right match, and the patients give their consent leading to retention throughout the process.

Deployment Mode Insights

In 2021, the web and cloud-based segment dominated the market with a revenue share of over 90.0% owing to the cloud computing model, which is easier to maintain with no upkeep charges. As in-house server infrastructure is not required, development costs are reduced. The integration time is significantly reduced and it may be accessed from any location. Data sharing is convenient and allows collaboration on different projects.

The on-premise model requires in-house infrastructure, software licensing, IT support, and lengthier integration times. Therefore, this model is costlier and less preferred. On the other hand, organizations with highly confidential data, including government and financial institutions, require an on-premises environment's security and privacy. Based on the deployment model, the market for clinical trials matching software is segmented into web and cloud-based, and on-premise.

End-use Insights

In 2021, the pharmaceutical and biotechnology companies segment dominated the market with a revenue share of over 40.0% due to the large number of clinical trials required for product launches. Based on end-use, the market is segmented into pharmaceutical and biotechnology companies, CROs, and medical device firms.

Global clinical trials matching software market share, by end use, 2021 (%)

The CROs segment is anticipated to expand at the fastest CAGR of 13.7% over the forecast period. CROs offer drug development through commercialization, pharmacovigilance, and post-approval services to manufacturing organizations with low R&D budgets. A sponsor (the entity wishing to research the safety and efficacy of the products) contracts a CRO, a project-by-project basis for clinical trials. The organizations that are unable to afford to conduct extensive clinical trials prefer to outsource these services. Hence, the demand for CROs is growing rapidly.

Regional Insights

In 2021, North America held the largest revenue share of over 50.0% owing to the growth in the adoption of the clinical trials matching software by the pharmaceutical and biotechnology companies in the U.S. In addition, the supportive government initiatives toward IT and AI-based solutions and the higher adoption of CTMS and patient matching software are contributing to the market growth in the region.

Asia Pacific is likely to register the fastest CAGR over the forecast period owing to the availability of a large patient pool in the region, enabling easier patient recruitment procedures. A large number of organizations are aiming to set up their R&D activities in the Asia Pacific, contributing to the market growth in the region. This growth can be attributed to the increase in the number of IT healthcare projects, booming economy, and overall improving healthcare infrastructure, especially in developing Asian countries, such as China and India.

Key Companies & Market Share Insights

The supportive government initiatives and rapidly evolving technology are further encouraging the market players to focus significantly on the new features and develop innovative products. In addition, rapid growth in the number of companies offering updated features, which can be customized, is contributing to the growth of the market in healthcare.

In the coming years, the manufacturers and software providers are most likely to rely on mergers, collaborations, partnerships, and acquisitions to strengthen their market positions. For instance, in December 2021, Optimapharm, a leading European clinical research organization, acquired SSS International. This acquisition helped the company is widening its portfolio of clinical research studies. Some prominent players in the global clinical trials matching software market include

  • IBM Clinical development

  • Antidote Technologies, Inc.

  • Clinical Trials Mobile Application

  • SSS International Clinical Research

  • Advarra

  • Aris Global

Clinical Trials Matching Software Market Report Scope

Report Attribute

Details

Market size value in 2022

USD 148.5 million

Revenue forecast in 2030

USD 396.1 million

Growth rate

CAGR of 13.8% from 2022 to 2030

Base year for estimation

2021

Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million & CAGR from 2022 to 2030

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

Segments covered

Deployment mode, end use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, Brazil, Mexico, South Africa

Key companies profiled

IBM Clinical development; Antidote Technologies, Inc.; Clinical Trials Mobile Application; SSS International Clinical Research; Advarra; Aris Global

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. 

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global clinical trials matching software market report based on deployment, end use, and region:

  • Deployment Mode Outlook (Revenue, USD Million, 2017 - 2030)
    • Web & Cloud Based

    • On-premise

  • End-use Outlook (Revenue, USD Million, 2017 - 2030)
    • Pharmaceutical & Biotechnology Companies

    • CROs

    • Medical Device Firms

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)
    • North America
      • U.S.

      • Canada

    • Europe
      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific
      • Japan

      • China

      • India

    • Latin America
      • Brazil

      • Mexico

    • Middle East & Africa
      • South Africa

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.